Gabriel Kristian Pedersen

Gabriel Kristian Pedersen


Gabriel Kristian Pedersen , Infektionsimmunologi / Adjuvans
T. +45 32688561 @.


My research aims at getting a better understanding of how vaccine adjuvants can be used to optimally protect against different disease targets. This includes:

  • Mechanistic studies of how vaccine adjuvants work
  • Developing novel adjuvants
  • Comparing adjuvants in various settings to understand which adjuvants are best suited for protecting against various pathogens and in cancer vaccines


  • Head of Adjuvant Research, Center for Vaccine Research


  • Pedersen GK, Andersen P, Christensen D. 2018. Immunocorrelates of CAF family adjuvants. Semin Immunol 39: 4-13
  • Wilkinson A, Lattmann E, Roces CB, Pedersen GK, Christensen D, Perrie Y. 2018. Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01. J Control Release 291:1-10
  • Schmidt ST, Pedersen GK, Neustrup MA, Korsholm KS, Rades T, Andersen P, Foged C, Christensen D. 2018. Induction of Cytotoxic T-Lymphocyte Responses Upon Subcutaneous Administration of a Subunit Vaccine Adjuvanted With an Emulsion Containing the Toll-Like Receptor 3 Ligand Poly(I:C). Front Immunol 9:898
  • Pedersen GK, Li X, Khoenkhoen S, Ádori M, Beutler B, Karlsson Hedestam GB. 2018. B-1a Cell Development in Splenectomized Neonatal Mice. Front Immunol 9:1738
  • Pedersen GK, Àdori M, Khoenkhoen S, Dosenovic P, Beutler B, Karlsson Hedestam GB. 2014. B-1a transitional cells are phenotypically distinct and are lacking in mice deficient in IκBNS. PNAS 111:E4119-26